Imidazopyrrolidine derivatives and their use in the treatment of disease

A compound of formula (I) or a pharmaceutically acceptable salt thereof,

• wherein
• A is selected from:
• B is selected from
• C is selected from:
• R1 is selected from H, halo and methyl;
• R2 is selected from halo, cyano, methyl, —CF3 and —O(C1-C4alkyl);
• R3 is selected from H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxyethyl-, and
• R4 is selected from:
• H;
• C1-C4alkyl;
• C3-C6cycloalkyl;
• pyridine, optionally substituted with one or two substituents selected from halo, cyano, —OH, —C1-C4alkyl, haloC1-C4alkyl, —O(haloC1-C4alkyl) and —C1-C4alkoxy;
• pyrimidin-5-yl, optionally substituted with one or two substituents selected from halo, cyano, —OH, —C1-C4alkyl, haloC1-C4alkyl, —O(haloC1-C4alkyl) and —C1-C4alkoxy;
• a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing 1 oxygen or 1 nitrogen atom or 1 oxygen and 1 nitrogen atom, and optionally substituted with one —C1-C6alkyl substituent, or optionally substituted with 1, 2, 3 or 4 methyl substituents, or optionally substituted with one substituent selected from —C(O) C1-C4alkyl, —C(O)OC1-C4alkyl, —C(O)NHC1-C4alkyl, and —S(O)2C1-C4alkyl;
• a 5-membered heteroaryl ring containing 1 or 2 nitrogen atoms, and optionally substituted with —C1-C4alkyl;
• a 5-membered heteroaryl ring containing 1 nitrogen atom and 1 oxygen or 1 sulphur atom, optionally substituted with one or two C1-C4alkyl;
• and
• R5 is H;
• R6 is selected from methyl and methoxy;
• and
• R7 is selected from methyl, —CH2F and —CHF2;
• provided that when
• A is
• B is
• C is
• R2 is selected from chloro, fluoro, trifluoromethyl, methyl and cyano;
• and
• R3 is isopropyl, isobutyl, cyclopropyl, cyclobutyl or cyclopentyl;
• then
• R4 is selected from:
• H;
• C1-C4alkyl;
• C3-C6cycloalkyl;
• a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing 1 or 2 heteroatoms selected from oxygen, sulphur and nitrogen, and optionally substituted with C1-C4alkyl;
• or a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing 1 oxygen or 1 nitrogen atom, and optionally substituted with one C1-C4alkyl substituent or optionally substituted with 1, 2, 3 or 4 methyl substituents;
• or a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing 1 oxygen or 1 nitrogen atom, or 1 oxygen and 1 nitrogen atom, and optionally substituted with one —C1-C6alkyl substituent, or optionally substituted with 1, 2, 3 or 4 methyl substituents, or optionally substituted with one substituent selected from —C(O) C1-C4alkyl, —C(O)OC1-C4alkyl, —C(O)NHC1-C4alkyl, and —S(O)2C1-C4alkyl;
• a 5-membered heteroaryl ring containing 1 or 2 nitrogen atoms, and optionally substituted with C1-C4alkyl;
• a 5-membered heteroaryl ring containing 1 nitrogen atom and 1 oxygen or 1 sulphur atom, optionally substituted with one or two C1-C4alkyl;
• wherein R8 is selected from OCH3, OH and OCF3;
• and R9 is halo;
• and wherein * indicates the point of attachment to the remainder of the molecule.